Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

Crizotinib is the standard of care for advanced non-small cell lung cancer (NSCLC) patients harboring the anaplastic lymphoma kinase (ALK) fusion gene, but resistance invariably develops. Unlike crizotinib, alectinib is a selective ALK tyrosine kinase inhibitor (TKI) with more potent antitumor effec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2016-03, Vol.76 (6), p.1506-1516
Hauptverfasser:	Isozaki, Hideko, Ichihara, Eiki, Takigawa, Nagio, Ohashi, Kadoaki, Ochi, Nobuaki, Yasugi, Masayuki, Ninomiya, Takashi, Yamane, Hiromichi, Hotta, Katsuyuki, Sakai, Katsuya, Matsumoto, Kunio, Hosokawa, Shinobu, Bessho, Akihiro, Sendo, Toshiaki, Tanimoto, Mitsune, Kiura, Katsuyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Cell Line, Tumor Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mice Mice, Inbred BALB C Mice, Nude Mutation - drug effects Mutation - genetics Oncogene Proteins, Fusion - genetics Protein Kinase Inhibitors - pharmacology Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Receptor Protein-Tyrosine Kinases - genetics Receptor, ErbB-3 - genetics Receptors, Somatomedin - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!